TAK-188
/ Takeda
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
March 18, 2026
TAK-188, an antibody-drug conjugate with a novel amanitin payload, disrupts immune suppression and leads to potent anti-tumor immunity through selective depletion of CCR8+ intratumoral regulatory T-cells
(AACR 2026)
- P1/2 | "In conclusion, TAK-188 robustly depletes CCR8+ cells both in vitro and in vivo and demonstrates anti-tumor activity as a single agent in nonclinical models. Based on this promising preclinical data, a Phase 1 study of TAK-188 has been opened (NCT07205718)."
ADC • IO biomarker • Oncology • Solid Tumor • CCR8 • CD4 • CD8
December 02, 2025
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=223 | Recruiting | Sponsor: Takeda | Not yet recruiting ➔ Recruiting
Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck
October 04, 2025
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=223 | Not yet recruiting | Sponsor: Takeda
New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck
1 to 3
Of
3
Go to page
1